New York, February 18, 2016 -- Moody's Investors Service placed the ratings of Truven Health Analytics Inc. ("Truven") under review for upgrade, including the company's B3 Corporate Family Rating and B3-PD Probability of Default Rating. Instrument ratings placed under review for upgrade include the B1 senior secured first lien credit facilities' rating and Caa2 senior unsecured notes' rating. This action follows the announcement that IBM Watson Health, a division of International Business Machines Corp. ("IBM") has announced plans to acquire Truven in a transaction valued at approximately $2.6 billion.

Vollständigen Artikel bei Moodys lesen